Biochemical modulation therapy for pancreatic cancer |
| |
Authors: | Koichi Hirata Mitsuhiro Mukaiya Susumu Yamamitsu Ikuo Oikawa Takeshi Takashima Tadashi Katsuramaki Kazuaki Sasaki Ryuichi Denno and Tetsuhiko Shirasaka |
| |
Institution: | (1) First Department of Surgery, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-ku, Sapporo, 060 Japan, JP;(2) Institute for Pathogenic Biochemistry in Medicine, Taiho Pharmaceutical Co., Misugidai, Hanno-city, Saitama, 357 Japan, JP |
| |
Abstract: | It is well known that the clinical course in most patients with advanced pancreatic cancer is not influenced substantially
by chemotherapy and/or radiotherapy. However, new chemotherapy, based on the synergistic antitumor activities of 5-fluorouracil
(5-FU) and cisplatin (CDDP) producing biochemical modulation in solid cancers diagnosed as adenocarcinoma, has recently been
reported to be effective. In gastrointestinal cancers, the optimal concentrations of each drug and the duration of the anticancer
effects, as well as adverse effects have been confirmed in pharmacodynamic studies. Our experience of this treatment for advanced
pancreatic cancer (stage IV) indicates the usefulness of the antitumor effect in terms of both effect on the tumor size in
unresectable patients and prognosis in resectable patients. These results were remarkable in patients diagnosed as stage IV
b and/or curability C. Although there were adverse effects, none were severe. However, anything compromising the patient's
quality of life must be prevented. Randomized prospective studies of the combination of 5-FU and CDDP are expected in the
near future.
Received for publication on July 29, 1998; accepted on July 31, 1998 |
| |
Keywords: | : biochemical modulation pancreatic cancer |
本文献已被 SpringerLink 等数据库收录! |
|